The Duogynon controversy and ignorance production in post-thalidomide West Germany

Reprod Biomed Soc Online. 2021 Oct 19:14:75-86. doi: 10.1016/j.rbms.2021.09.003. eCollection 2022 Mar.

Abstract

This article examines the West German controversy over Duogynon, a 'hormone pregnancy test' and the drug at the centre of the first major, international debate over iatrogenic birth defects in the post-thalidomide era. It recovers an asymmetrical power struggle over the uneven distribution of biomedical knowledge and ignorance (about teratogenic risk) that pitted parent-activists, whistleblowers and investigative journalists against industrialists, scientific experts and government officials. It sheds new light on the nexus of reproduction, disability, epidemiology and health activism in West Germany. In addition, it begins to recover an internationally influential discourse that, in the post-thalidomide world, seems to have resuscitated antenatal drug use as safe until proven harmful.

Keywords: Congenital malformations; Health activism; Ignorance production; Pregnancy testing; Schering AG; West Germany.